Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
67°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
28.66
-0.02 (-0.05%)
Streaming Delayed Price
Updated: 2:01 PM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
99
100
Next >
Better Dividend Stock: Pfizer vs. AbbVie
February 05, 2024
Both offer above-average yields but which can deliver the most dividend income over the long run?
Via
The Motley Fool
CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development
February 05, 2024
Click here to learn more about CytoReason and how to invest through OurCrowd.
Via
Benzinga
The Bull Market Left These 3 Stocks Behind, but They're Buys Right Now
February 04, 2024
Sometimes, undervalued market laggards have what it takes to catch up over the long haul.
Via
The Motley Fool
1 Beaten-Down Dividend Stock to Avoid in 2024, and 1 to Consider Buying and Holding Forever
February 04, 2024
These two companies have dramatically different futures in store.
Via
The Motley Fool
3 Fabulous Dividend Stocks to Buy in February
February 04, 2024
These stocks offer great dividends and more.
Via
The Motley Fool
Benzinga Bulls And Bears: Meta, Tesla, AMD And Crypto Analyst Predicts That 'DOGE Is Gonna Pop'
February 03, 2024
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
Is the Worst Over for Pfizer?
February 01, 2024
Pfizer shares sank 43% last year.
Via
The Motley Fool
Peeling Back The Layers: Exploring Pfizer Through Analyst Insights
January 31, 2024
Via
Benzinga
ROSEN, A LONGSTANDING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
February 02, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
ROSEN, A LONGSTANDING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
February 02, 2024
WHY: NEW YORK, NY - (NewMediaWire) - February 02, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Recent Stock Purchase January 2024
February 02, 2024
With February already underway and the markets on a nice uptrend, I decided to add to some of my lagging existing positions.
Via
Talk Markets
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat
February 02, 2024
Bristol Myers earnings came in above expectations, although Opdivo sales were slower than expected. BMY stock gained.
Via
Investor's Business Daily
Million-Dollar Bets: 7 Stocks to Buy Before They Blast Off
February 02, 2024
Seven stocks set to soar: Foundries to pharma, finance's evolution, and digital transformation—unlock million-dollar opportunities.
Via
InvestorPlace
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
February 02, 2024
From
Genmab A/S
Via
Business Wire
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
February 01, 2024
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a...
Via
Benzinga
Exposures
COVID-19
Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market
February 01, 2024
Pfizer is in Wall Street's doghouse, but don't despair. At its current price, value seekers ought to relish the opportunity to buy PFE stock.
Via
InvestorPlace
What's Going On With Pfizer Stock Today?
February 01, 2024
Pfizer stock update: Q4 earnings beat expectations with adjusted EPS of $0.10, while FY2023 shows a 72% YoY decline. Explore 2024 R&D plans and recent program discontinuations.
Via
Benzinga
Topics
Earnings
Exposures
Financial
Biotech And Medtech Portfolio Notes On A Fed Day
January 31, 2024
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23%
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
January 31, 2024
Is your portfolio is in dire need of making new all-time highs? A new economic cycle is to send these penny stocks with potential up.
Via
InvestorPlace
Listen to Wall Street and Buy These 3 Stocks Now
January 31, 2024
With a Wall Street recommended stock, you have the comfort of expert analysis along with a possible market-moving influence.
Via
InvestorPlace
3 Standout Stocks That Crushed Q4 Earnings Estimates
January 31, 2024
These three stocks crushing Q4 earnings are on the rise after the companies behind them closed the year with a bang.
Via
InvestorPlace
Novavax Layoffs 2024: What to Know About the Latest NVAX Job Cuts
January 31, 2024
The Novavax layoffs are coming for 12% of the company's global workforce. However, NVAX stock itself could shock the market.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares
January 31, 2024
Eli Lilly to report strong Q4 earnings thanks to successful diabetes treatments, while rivals like Novo Nordisk and Pfizer are also vying for a share of the weight-loss market.
Via
Benzinga
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
January 31, 2024
Colds, flu and RSV aren't the only viral illnesses people have to worry about this winter. A new variant of COVID-19 is rapidly spreading, reminding the world of just how dangerous this virus is.
Via
Benzinga
Exposures
COVID-19
Best Income Stocks 2024
January 31, 2024
The pros and cons of 7 companies in 4 different sectors.
Via
Talk Markets
Pfizer (PFE) Q4 2023 Earnings Call Transcript
January 30, 2024
PFE earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Pfizer Stock Was Jumping Today, but Then Gave Up Its Gains
January 30, 2024
The drugmaker's Q4 results were better than many expected, but still not good enough to spark a sustained rally.
Via
The Motley Fool
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.
Via
Benzinga
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.